Nemocnice Na Homolce
- Address
- lock Available on a paid plan
Nemocnice Na Homolce - Advanced Oncology and Cerebrovascular Research
Nemocnice Na Homolce is a distinguished clinical research institution conducting innovative trials in oncology and neurovascular medicine. The center demonstrates expertise in evaluating novel therapeutic approaches for complex conditions, including advanced cancer treatments and stroke prevention strategies.
- Metastatic castration-resistant prostate cancer treatment using antibody-drug conjugates
- Stroke prevention following acute ischemic events and high-risk transient ischemic attacks
- Novel anticoagulation strategies with FXIa inhibitors for non-cardioembolic stroke prevention
The research center actively participates in Phase III multicenter trials evaluating cutting-edge therapies, including vobramitamab duocarmazine for advanced prostate malignancies and asundexian for secondary stroke prevention. Their work focuses on radiographic progression assessment using standardized criteria and comparative safety evaluations of breakthrough treatments against established care protocols, contributing to the advancement of precision medicine in both oncological and cerebrovascular disease management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Na Homolce
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK) | Macrogenics Inc. | Phase II | Not Recruiting | May 2023 | Jan 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Asundexian | 1 | Unknown | 2023-01-18 | 2023-01-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.